Bruno Dubois, Nicolas Villain, Giovanni B Frisoni, Gil D Rabinovici, Marwan Sabbagh, Stefano Cappa, Alexandre Bejanin, Stéphanie Bombois, Stéphane Epelbaum, Marc Teichmann, Marie-Odile Habert, Agneta Nordberg, Kaj Blennow, Douglas Galasko, Yaakov Stern, Christopher C Rowe, Stephen Salloway, Lon S Schneider, Jeffrey L Cummings, Howard H Feldman
In 2018, the US National Institute on Aging and the Alzheimer's Association proposed a purely biological definition of Alzheimer's disease that relies on biomarkers. Although the intended use of this framework was for research purposes, it has engendered debate and challenges regarding its use in everyday clinical practice. For instance, cognitively unimpaired individuals can have biomarker evidence of both amyloid β and tau pathology but will often not develop clinical manifestations in their lifetime...
June 2021: Lancet Neurology